报告题目：BioMEMS tools forsingle-cell functional omics and the monitoring of cancer immunotherapy
报告人：Rong Fan教授，耶鲁大学生物医学工程系
时间：6月19日（星期二）下午3点
地点：生物电子学国家重点实验室三楼会议室
欢迎老师和同学参加！
附报告摘要和报告人简介：
BioMEMS tools for single-cell functional omics and themonitoring of cancer immunotherapy
Rong Fan, Ph.D.
Department of Biomedical Engineering, Yale University
Despite recent advances in single-cell genomic,transcriptional and mass cytometric profiling, it remains a challenge tocollect highly multiplexed measurements of proteins produced from single cellsfor comprehensive analysis of immune functional state. My talk will bediscussing a novel bioMEMS device technology for single-cell proteomicprofiling, in particular, the co-detection of 40+ immune effector proteins suchas cytokines/chemokines at the level of single cells, representing the highestmultiplexing recorded to date for a single-cell protein secretion assay. I willdescribe how this microchip technology called IsoCode was conceived at thebeginning, evolved over generations, further integrated with a fully automatedsingle-cell processing platform called IsoLight comprising high-resolutionoptics, precision fluid handling and live cell incubation in the same system totruly enable robust and reproducible functional proteomics data at thesingle-cell level. It has been in the pipeline of commercialization atIsoPlexis and adopted by pharmaceutical companies like Novartis, Kite Pharma (aGilead Company), Bellicum, and many others to evaluate their immunotherapyproducts. This microchip technology allowed for the full-spectrumdissection of T cell functions including genetically engineered chimericantigen receptor T cells (CAR-T) in the treatment of patients with acutelymphoblastic leukemia or non-Hodgkin’s lymphoma. Our data obtained from amedium-scale clinical trial with CD19 CAR-T cells demonstrated strongassociation between CAR-T cells’ polyfunctionality (the ability for a single Tcell to co-produce multiple immune effector proteins) and patient response,which opens up new opportunities for predicting not only therapeutic efficacybut also potentially life-threatening immunotoxicity. All these underscore theimportance to measure functional proteomic heterogeneity even in phenotypicallyidentical cell populations in order to evaluate the quality of cell-basedtherapeutics or to monitor patient responses for precision medicine. The smalldevices described above really enabled the wide-spread application in clinicalmonitoring of cancer immunotherapies.
Biosketch
Dr. Rong Fan is Associate Professor (tenured) ofBiomedical Engineering at Yale University. He received a B.S. in AppliedChemistry from University of Science and Technology in China, a Ph.D. inChemistry from the University of California at Berkeley, and then completed hispostdoctoral training at California Institute of Technology, prior to launchinghis own research laboratory at Yale University in 2010. His current researchinterest is focused on developing single-cell micro/nano-technologies tointerrogate functional cellular heterogeneity and inter-cellular signalingnetwork in human health and disease (e.g., cancer and autoimmunity). Hedeveloped a microchip technology that, for the first time, permits simultaneousmeasurement of 42 immune effector proteins in single cells, representing thehighest multiplexing to date for a single-cell protein secretion assay. He isalso working to develop high-throughput technologies for co-analysis ofsingle-cell epigenomic, transcriptomic, and proteomic profiles. Applying thesetechnologies to human hematopoietic malignancies and systemic autoimmunediseases has revealed new biological insights and new targets potentially forearly diagnosis or therapeutic intervention. He co-founded IsoPlexis, a lifescience tool company that aims to develop single-cell proteomics microchips forcancer immunotherapy monitoring and companion diagnostics. He is a member ofScientific Advisory Board (SAB) of Bio-Techne, a leading life sciencetools&reagents company. He is the recipient of numerous awardsincluding the National Cancer Institute’s Howard Temin CareerTransition Award, the NSF CAREER Award, and the Packard Fellowship for Scienceand Engineering.